Charles River Laboratories Inte – Consensus Indicates Potential 9.3% Upside

Broker Ratings

Charles River Laboratories Inte with ticker code (CRL) have now 12 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 300 and 241 and has a mean target at 269.25. Now with the previous closing price of 246.28 this would indicate that there is a potential upside of 9.3%. The 50 day MA is 207.36 and the 200 moving average now moves to 241.38. The market capitalisation for the company is $12,363m. Find out more information at:

The potential market cap would be $13,516m based on the market concensus.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Charles River Laboratories International, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International was founded in 1947 and is headquartered in Wilmington, Massachusetts.

You might also enjoy reading  Charles River Laboratories Inte - Consensus Indicates Potential 22.2% Upside
Find more news, interviews, share price & company profile here for:

    Good news travels fast (but only if you make that happen). Share on:


      AIM All Share Index